CHEK1 and small cell lung carcinoma: Prexasertib (LY2606368), a second-generation CHK1 inhibitor, has been studied both as a monotherapy and in combination with chemotherapy in models of platinum-sensitive and -resistant small-cell lung cancer (SCLC) [124].